Q-omics provides the consensus-scored FAM230A profile across patient tissues and cancer cell-line models. FAM230A expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, FAM230A is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, FAM230A RNA expression shows 5,344 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and LIHC as cancer lineages where FAM230A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM230A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM230A survival associations across molecular data types. FAM230A RNA expression shows survival associations in the most cancer types (9), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM230A RNA expression–survival associations across cancer types. High FAM230A expression shows unfavorable associations in STAD, SKCM, COAD, BLCA, BRCA and LIHC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for FAM230A RNA expression.
This table summarizes FAM230A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM230A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM230A shows higher tumor expression in LIHC and THCA. The LIHC box plot shows higher FAM230A RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .038).
This table shows molecular features associated with FAM230A in patient tissues and cancer cell lines. In patient samples, FAM230A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM230A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
